留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
王彦卿, 陈野野, 黄诚, 郭峰, 张晔, 张杰石, 郭超, 王桂阁, 李单青. 肺类癌的诊治进展[J]. 协和医学杂志, 2021, 12(3): 366-372. doi: 10.3969/j.issn.1674-9081.2020.00.006
引用本文: 王彦卿, 陈野野, 黄诚, 郭峰, 张晔, 张杰石, 郭超, 王桂阁, 李单青. 肺类癌的诊治进展[J]. 协和医学杂志, 2021, 12(3): 366-372. doi: 10.3969/j.issn.1674-9081.2020.00.006
WANG Yanqing, CHEN Yeye, HUANG Cheng, GUO Feng, ZHANG Ye, ZHANG Jieshi, GUO Chao, WANG Guige, LI Shanqing. Progress in the Diagnosis and Treatment of Pulmonary Carcinoids[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 366-372. doi: 10.3969/j.issn.1674-9081.2020.00.006
Citation: WANG Yanqing, CHEN Yeye, HUANG Cheng, GUO Feng, ZHANG Ye, ZHANG Jieshi, GUO Chao, WANG Guige, LI Shanqing. Progress in the Diagnosis and Treatment of Pulmonary Carcinoids[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 366-372. doi: 10.3969/j.issn.1674-9081.2020.00.006

肺类癌的诊治进展

doi: 10.3969/j.issn.1674-9081.2020.00.006
基金项目: 

国家重点研发计划 2020YFB1313700

详细信息
    通讯作者:

    李单青 电话:010-69152630,E-mail:lsq6768@sohu.com

  • 中图分类号: R730.4; R730.5

Progress in the Diagnosis and Treatment of Pulmonary Carcinoids

Funds: 

National Key Research and Development Program of China 2020YFB1313700

More Information
    Corresponding author: LI Shanqing Tel: 86-10-69152630, E-mail: lsq6768@sohu.com
  • 摘要: 肺类癌(pulmonary carcinoids,PCs)是一种分化较好的低级别肺部神经内分泌肿瘤。PCs与常见的肺癌及其他肺部神经内分泌肿瘤相比,由于临床症状的复杂性和生物学的异质性,其具有不同的病理学分类方法、临床表现和治疗方式。对于大多数局限性PCs患者,手术是可治愈的治疗方式,通常不推荐辅助治疗。对于晚期PCs患者,常需全身综合治疗。本文就PCs的流行病学、诊断标准、病理学分类及常用治疗方法进行综述,以期提高临床医生的认识,促进PCs治疗的规范化和标准化,使更多患者获益。
    作者贡献: 王彦卿负责查阅文献、构思及撰写文章;黄诚、郭峰、张晔、张杰石、郭超、王桂阁参与文献检索及文章撰写;李单青、陈野野负责文章修订。
    利益冲突: 无
  • 表  1  进展期、晚期/转移性分化良好的肺部神经内分泌肿瘤药物治疗方案选择[16, 35-36]

    代表方案 药物 指征
    SSA 奥曲肽,兰瑞肽 SSTR表达强阳性的TC或AC
    mTOR抑制剂 依维莫司 任意类型的TC或AC
    基于铂类的化疗 替莫唑胺±卡培他滨 SSTR表达阴性的快速进展期的TC或AC
    基于替莫唑胺的化疗 顺铂+依托泊苷 SSTR表达阴性的快速进展期的AC
    肽受体放射性核素治疗 177Lu-octreotate SSTR表达强阳性的TC或AC
    SSA:生长抑素类似物;SSTR:生长抑素受体;TC:典型类癌;AC:不典型类癌;mTOR:哺乳动物雷帕霉素靶蛋白
    下载: 导出CSV
  • [1] Torniai M, Scortichini L, Tronconi F, et al. Systemic treatment for lung carcinoids: from bench to bedside[J]. Clin Transl Med, 2019, 8: 22. doi:  10.1186/s40169-019-0238-5
    [2] Volante M, Mete O, Pelosi G, et al. Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocr-ine Tumors: What Do Pathologists Need to Know?[J]. Endocr Pathol, 2021, 32: 154-168. doi:  10.1007/s12022-021-09668-z
    [3] Sadowski SM, Christ E, Bédat B, et al. Nationwide multicenter study on the management of pulmonary neuroendocr-ine(carcinoid) tumors[J]. Endocr Connect, 2018, 7: 8-15. doi:  10.1530/EC-17-0271
    [4] Fernandez-Cuesta L, Peifer M, Lu X, et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids[J]. Nat Commun, 2014, 5: 3518. doi:  10.1038/ncomms4518
    [5] Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer[J]. Nat Genet, 2012, 44: 1104-1110. doi:  10.1038/ng.2396
    [6] Hörsch D, Schmid KW, Anlauf M, et al. Neuroendocrine tumors of the bronchopulmonary system(typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany[J]. Oncol Res Treat, 2014, 37: 266-276. http://www.karger.com/Article/Abstract/362430
    [7] Wolin EM. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung[J]. Chest, 2017, 151: 1141-1146. doi:  10.1016/j.chest.2016.06.018
    [8] Hilal T. Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management[J]. Ther Adv Med Oncol, 2017, 9: 189-199. doi:  10.1177/1758834016678149
    [9] Kaltsas G, Androulakis II, de Herder WW, et al. Paraneoplastic syndromes secondary to neuroendocrine tumours[J]. Endocr Relat Cancer, 2010, 17: R173-R193. doi:  10.1677/ERC-10-0024
    [10] Hannah-Shmouni F, Stratakis CA, Koch CA. Flushing in(neuro)endocrinology[J]. Rev Endocr Metab Disord, 2016, 17: 373-380. doi:  10.1007/s11154-016-9394-8
    [11] 黄诚, 陈野野, 李单青, 等. 胸部神经内分泌肿瘤所致异位促肾上腺皮质激素综合征诊疗及预后[J]. 协和医学杂志, 2017, 8: 147-153. doi:  10.3969/j.issn.1674-9081.2017.03.012

    Huang C, Chen YY, Li SQ, et al. Ectopic Adrenocorticotropic Hormone Syndrome Caused by Thoracic NeuroendocrineTumors: Surgical Treatment and Prognosis Factors[J]. Xie He Yi Xue Za Zhi, 2017, 8: 147-153. doi:  10.3969/j.issn.1674-9081.2017.03.012
    [12] Dynkevich Y, Rother KI, Whitford I, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive[J]. Endocr Rev, 2013, 34: 798-826. doi:  10.1210/er.2012-1033
    [13] 陈野野, 田震寰, 周小昀, 等. 支气管肺类癌的临床特点及预后因素分析[J]. 协和医学杂志, 2018, 9: 352-357. doi:  10.3969/j.issn.1674-9081.2018.04.012

    Chen YY, Tian ZH, Zhou XY, et al. Diagnostic and Therapeutic Features of Bronchopulmonary Carcinoid[J]. Xie He Yi Xue Za Zhi, 2018, 9: 352-357. doi:  10.3969/j.issn.1674-9081.2018.04.012
    [14] Meisinger QC, Klein JS, Butnor KJ, et al. CT features of peripheral pulmonary carcinoid tumors[J]. AJR Am J Roentgenol, 2011, 197: 1073-1780. doi:  10.2214/AJR.10.5954
    [15] Benson RE, Rosado-de-Christenson ML, Martínez-Jiménez S, et al. Spectrum of pulmonary neuroendocrine proliferations and neoplasms[J]. Radiographics, 2013, 33: 1631-1649. doi:  10.1148/rg.336135506
    [16] Prinzi N, Rossi RE, Proto C, et al. Recent Advances in the Management of Typical and Atypical Lung Carcinoids[J]. Clin Lung Cancer, 2020, S1525-7304(20)30347-8. doi: 10.1016/j.cllc.2020.12.004.
    [17] Baxi AJ, Chintapalli K, Katkar A, et al. Multimodality Imaging Findings in Carcinoid Tumors: A Head-to-Toe Spectrum[J]. Radiographics, 2017, 37: 516-536. doi:  10.1148/rg.2017160113
    [18] Kaifi JT, Kayser G, Ruf J, et al. The Diagnosis and Treatment of Bronchopulmonary Carcinoid[J]. Dtsch Arztebl Int, 2015, 112: 479-485. http://www.ncbi.nlm.nih.gov/pubmed/26214234
    [19] Phan AT, Oberg K, Choi J, et al. NANETS consensus guideline for the diagnosis and management of neuroendocr-ine tumors: well-differentiated neuroendocrine tumors of the thorax(includes lung and thymus)[J]. Pancreas, 2010, 39: 784-798. doi:  10.1097/MPA.0b013e3181ec1380
    [20] Shimosato Y. [Histological Typing of Lung and Pleural Tumors(3rd edition): Malignant epithelial tumors][J]. Nihon Rinsho, 2002, 60: 123-131. http://europepmc.org/abstract/MED/12101640
    [21] Galateau-Salle F, Churg A, Roggli V, et al. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification[J]. J Thorac Oncol, 2016, 11: 142-154. doi:  10.1016/j.jtho.2015.11.005
    [22] Rindi G, Klersy C, Inzani F, et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal[J]. Endocr Relat Cancer, 2013, 21: 1-16. http://europepmc.org/abstract/med/24344249
    [23] Pelosi G, Pattini L, Morana G, et al. Grading lung neuroendocrine tumors: Controversies in search of a solution[J]. Histol Histopathol, 2017, 32: 223-241.
    [24] Stathopoulos GP, Malamos NA, Markopoulos C, et al. The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes[J]. Anticancer Drugs, 2014, 25: 950-957. doi:  10.1097/CAD.0000000000000123
    [25] Tang LH, Gonen M, Hedvat C, et al. Objective quantifica-tion of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods[J]. Am J Surg Pathol, 2012, 36: 1761-1770. doi:  10.1097/PAS.0b013e318263207c
    [26] Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming(Eighth) Edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol, 2016, 11: 39-51. doi:  10.1016/j.jtho.2015.09.009
    [27] Volante M, Gatti G, Papotti M. Classification of lung neuroendocrine tumors: lights and shadows[J]. Endocrine, 2015, 50: 315-319. doi:  10.1007/s12020-015-0578-x
    [28] Neyman K, Sundset A, Naalsund A, et al. Endoscopic treatment of bronchial carcinoids in comparison to surgical resection: a retrospective study[J]. J Bronchology Interv Pulmonol, 2012, 19: 29-34. doi:  10.1097/LBR.0b013e3182446b52
    [29] Lim E, Yap YK, De Stavola BL, et al. The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors[J]. J Thorac Cardiovasc Surg, 2005, 130: 969-972. doi:  10.1016/j.jtcvs.2005.05.041
    [30] García-Yuste M, Matilla JM, Cueto A, et al. Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung[J]. Eur J Cardiothorac Surg, 2007, 31: 192-197. doi:  10.1016/j.ejcts.2006.11.031
    [31] Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer[J]. J Thorac Oncol, 2017, 12: 1109-1121. doi:  10.1016/j.jtho.2017.04.011
    [32] Filosso PL, Oliaro A, Ruffini E, et al. Outcome and prognostic factors in bronchial carcinoids: a single-center experience[J]. J Thorac Oncol, 2013, 8: 1282-1288. doi:  10.1097/JTO.0b013e31829f097a
    [33] Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine(carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids[J]. Ann Oncol, 2015, 26: 1604-1620. doi:  10.1093/annonc/mdv041
    [34] Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary[J]. Neuroendocrinology, 2012, 95: 157-176. doi:  10.1159/000335597
    [35] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of(177)Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. doi:  10.1056/NEJMoa1607427
    [36] Vinik AI, Wolin EM, Liyanage N, et al. Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment(Elect): A Randomized, Double-Blind, Placebo-Controlled Trial[J]. Endocr Pract, 2016, 22: 1068-1080. doi:  10.4158/EP151172.OR
    [37] Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med, 2014, 371: 1556-1557. http://smartsearch.nstl.gov.cn/paper_detail.html?id=af94dd659568d7a666a05ff89f7924e6
    [38] Sullivan I, Le Teuff G, Guigay J, et al. Antitumour activity of somatostatin analogues in sporadic, progressive, meta-static pulmonary carcinoids[J]. Eur J Cancer, 2017, 75: 259-267. doi:  10.1016/j.ejca.2016.11.034
    [39] Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001(everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study[J]. J Clin Oncol, 2008, 26: 4311-4318. doi:  10.1200/JCO.2008.16.7858
    [40] Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase Ⅱ trial[J]. J Clin Oncol, 2010, 28: 69-76. doi:  10.1200/JCO.2009.24.2669
    [41] Anthony LB, Pavel ME, Hainsworth JD, et al. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase Ⅲ RADIANT-2 Trial[J]. Neuroendocrinology, 2015, 102: 18-25. doi:  10.1159/000381715
    [42] Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract(RADIANT-4): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2016, 387: 968-977. doi:  10.1016/S0140-6736(15)00817-X
    [43] Detterbeck FC. Management of carcinoid tumors[J]. Ann Thorac Surg, 2010, 89: 998-1005. doi:  10.1016/j.athoracsur.2009.07.097
    [44] Forde PM, Hooker CM, Boikos SA, et al. Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report[J]. J Thorac Oncol, 2014, 9: 414-418. doi:  10.1097/JTO.0000000000000065
    [45] Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors[J]. Clin Cancer Res, 2007, 13: 2986-2991. doi:  10.1158/1078-0432.CCR-06-2053
    [46] Kotteas EA, Syrigos KN, Saif MW. Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors[J]. Onco Targets Ther, 2016, 9: 699-704. http://pubmedcentralcanada.ca/pmcc/articles/PMC4755420/
    [47] Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy(PRRNT) in neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2013, 40: 800-816. doi:  10.1007/s00259-012-2330-6
    [48] Reubi JC, Waser B. Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs[J]. J Nucl Med, 2015, 56: 613-615. doi:  10.2967/jnumed.114.153189
    [49] Ianniello A, Sansovini M, Severi S, et al. Peptide receptor radionuclide therapy with(177)Lu-DOTATATE in adv-anced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and(18)F-FDG PET[J]. Eur J Nucl Med Mol Imaging, 2016, 43: 1040-1046. doi:  10.1007/s00259-015-3262-8
  • 加载中
表(1)
计量
  • 文章访问数:  116
  • HTML全文浏览量:  10
  • PDF下载量:  23
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-08-29
  • 录用日期:  2020-01-10
  • 网络出版日期:  2020-08-11
  • 刊出日期:  2021-05-30

目录

    /

    返回文章
    返回